Formulation White Papers & Case Studies

  1. The Importance Of Polymorph Screenings 5/6/2026

    Discover how systematic polymorph screening reduces development risk, safeguards product performance, and enables confident solid‑form selection across the drug development lifecycle.

  2. Deciphering Nanoparticle Properties With AF4 5/6/2026

    Discover how risk‑based, phase‑appropriate synthesis enables safe, efficient production of highly potent compounds while balancing speed, worker safety, and regulatory readiness in early development.

  3. Drug Substance For Early Clinical Phase Initiation 5/6/2026

    Explore how proactive nitrosamine impurity risk assessment protects early clinical drug supply, minimizes development delays, and enables confident progression to first‑in‑human studies.

  4. Late‑Stage Progress In Excipients For Precision Nanomedicine 5/6/2026

    View late‑stage development and GMP manufacturing of novel excipients for nanomedicines, emphasizing regulatory rigor, process optimization, analytics, and scale‑up for lipid‑based delivery systems.

  5. Why Pharmaceutical Scientists Trust The Discovery Core Rheometer 5/1/2026

    Drug formulations demand more than single‑point viscosity data. Explore how rheology reveals stability, flow, and structural behavior across suspensions, topicals, and injectables.

  6. Bispecific T- Cell Engager (BiTE) Screening, Automated Pipeline 5/1/2026

    View automated, high‑throughput BiTE screening in mammalian cells, enabling rapid discovery of efficacious variants through precise genomic integration and scalable workflows.

  7. De-Risk Nucleic Acid Therapeutics Through Strategic Outsourcing 4/20/2026

    Bringing a nucleic acid therapy to market requires specialized formulation and development knowledge. Innovators need rigorous analytical and formulation strategies to achieve stability and quality.

  8. Life Cycle Assessment Of Extended Use Strategies For Single-Use Assemblies 4/17/2026

    Examine how extending the use of single‑use assemblies can significantly reduce emissions, resource consumption, and waste in bioprocessing, offering a data‑backed path toward sustainability.

  9. Why Tailored CDMO Support Is A Non-Negotiable In Sterile Fill-Finish 4/13/2026

    Modern injectable programs require adaptable manufacturing strategies. Learn how flexibility, technical depth, and collaboration reduce complexity, manage change, and protect long‑term supply.

  10. Beyond Particle Counting: Why Modern Biologics Need Particle Forensics 4/8/2026

    High particle counts don’t always mean high risk. Identifying particle type and origin—not just quantity—avoids false alarms, protects timelines, and turns data into action.